NCT07776548Not yet recruiting
Development and Validation of a Circulating Tumour DNA Marker for Pre-neoplastic Colorectal Tumours.
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
The goal of this prospective interventional biomarker development and validation study is to determine whether circulating tumour DNA (ctDNA) can be detected in patients with large pre-neoplastic colorectal lesions undergoing endoscopic resection and whether ctDNA can be used to identify local recurrence after resection. The main questions it aims to answer are: * Can advanced colorectal laterally spreading tumours (LSTs) shed detectable ctDNA into the bloodstream before endoscopic resection? * Can ctDNA measured at the first surveillance colonoscopy detect or predict local recurrence after endoscopic resection? Participants will: * Provide a blood sample before their planned endoscopic resection procedure for ctDNA analysis. * Undergo standard endoscopic resection of their colorectal lesion. * Allow collection and molecular analysis of tissue samples obtained from the resected lesion. * Allow researchers to collect clinical, endoscopic, pathological, and molecular data from their medical records for research purposes. The study does not alter the standard clinical management, resection technique, or surveillance schedule. The only study-specific procedures are blood sample collections performed during routine intravenous catheter placement for the participant's endoscopic procedures.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- First submitted
- 30 Jul 2026
- Start date
- Jan 2027
- Primary completion date
- Jun 2028
- Lead sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
- Diseases
- Colorectal cancer
- NCT number
- NCT07776548
What you commit to
- Study type: Interventional
- Planned participants: 110
- From Jan 2027 to the primary completion date, Jun 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known concurrent or prior colorectal cancer, or another active malignancy that could contribute circulating tumour DNA.
Other
- Lesion \< 10 mm.
- Inability to provide informed consent.
Who the study is looking for
- Age ≥ 18 years.
- Referred for resection of a large (≥ 10 mm) colorectal laterally spreading tumour (LST).
- Lesion judged amenable to endoscopic resection by the treating endoscopist.
- Able to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.